Mild Facial Paresis in a recipient of Gam-COVID-Vac Vaccine: A Case Report.

Mild Facial Paresis in a recipient of Gam-COVID-Vac Vaccine: A Case Report. | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Case Report Mild Facial Paresis in a recipient of Gam-COVID-Vac Vaccine: A Case Report. Negin Mahmoudi Hamidabad, Amir Reza Mafi, Meysam Abolmaali This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1847958/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Facial paralysis has previously been reported as a rare side effect of vaccines such as influenza (1). Among COVID-19 vaccines, there have been reports of facial paralysis associated with BNT162 and 2019-nCoV Vaccine mRNA-1273 vaccines (2). To our knowledge, there is no report of facial paresis due to the Gam-COVID-Vac vaccination. Gam-COVID-Vac vaccine (rAd26 and rAd5 vector-based) was introduced in Russia in August 2020. In September 2020 the first peer-reviewed study of its I/II phase clinical trials was published and no serious side effects were reported (3). The results of the Gam-COVID-Vac phase III clinical trial also had no report of serious side effects (4). The Gam-COVID-Vac vaccine is reported to have above 90 percent efficacy, but still, there is no official report on its safety and efficacy by international organizations (5). Iran is among the countries using the Gam-COVID-Vac vaccine. Despite using this vaccine in many countries, there has been no official report of facial paresis/palsy in association with it. Here, we present a case of mild facial paresis that occurred shortly after Gam-COVID-Vac vaccine administration in a female healthcare worker. Neurology COVID-19 vaccine Gam-COVID-Vac facial paresis Figures Figure 1 Background Facial paralysis has previously been reported as a rare side effect of vaccines such as influenza ( 1 ). Among COVID-19 vaccines, there have been reports of facial paralysis associated with BNT162 and 2019-nCoV Vaccine mRNA-1273 vaccines ( 2 ). To our knowledge, there is no report of facial paresis due to the Gam-COVID-Vac vaccination. Gam-COVID-Vac vaccine (rAd26 and rAd5 vector-based) was introduced in Russia in August 2020. In September 2020 the first peer-reviewed study of its I/II phase clinical trials was published and no serious side effects were reported ( 3 ). The results of the Gam-COVID-Vac phase III clinical trial also had no report of serious side effects ( 4 ). The Gam-COVID-Vac vaccine is reported to have above 90 percent efficacy, but still, there is no official report on its safety and efficacy by international organizations ( 5 ). Iran is among the countries using the Gam-COVID-Vac vaccine. Despite using this vaccine in many countries, there has been no official report of facial paresis/palsy in association with it. Here, we present a case of mild facial paresis that occurred shortly after Gam-COVID-Vac vaccine administration in a female healthcare worker. Case Presentation A 34-year-old female healthcare worker presented to the emergency department with a unilateral facial weakness a day after receiving the first dose of the Gam-COVID-Vac vaccine. She had a history of migraine attacks (under treatment with Topiramate 25 mg twice a day and Propranolol 40 mg daily). She received the vaccine on February 28th, 2021. A few hours after receiving the vaccine, she developed myalgia, low-grade fever, and rhinorrhea which resolved spontaneously within 3 hours. The next morning, she woke up with a right-sided otalgia and posterior auricular pain which was then followed by unilateral facial weakness (Fig. 1 ). In physical examination, the patient had no fever and vital signs were stable. The forehead skin was normal. The Marionette line and nasolabial fold were slightly flattened on the right side and the patient had a mild asymmetrical smile. The eyelids were normal on examination. Ears were normal on examination. There was no evidence of skin rash in physical examination. The review of systems was normal except for the auricular pain and facial weakness. Brain magnetic resonance imaging appeared normal. Complete blood count and C-reactive protein also were normal. She did not receive oral glucocorticoids due to the mild state of the symptoms. The patient was followed for one month and her facial paresis resolved after four sessions of physiotherapy (Fig. 1 ). A month later, she received the second dose of the vaccine and reported no serious adverse effects. Discussion In this study, a case of mild facial paresis following the Gam-COVID-Vac vaccination has been reported that resolved after a few sessions of physiotherapy and did not recur after receiving the second dose of the vaccine. Gam-COVID-Vac was the first registered COVID-19 vaccine in the world but has not been approved by the world health organization, yet. Based on the literature, there has not been any report of facial paresis or palsy associated with the Gam-COVID-Vac vaccine. In a study, the prevalence of facial paralysis-related side effects was 0.6 percent among all side effects and was higher in female vaccine recipients (67.8%). Also, the prevalence of facial palsy was 0.5 percent with other viral vaccines and 0.7 percent with the Influenza vaccine ( 2 ). Facial palsy can occur due to viral infections, trauma, pregnancy, or without known etiology. It is usually self-limiting in nature and may resolve spontaneously ( 6 ). There are many reports regarding the incidence of facial palsy in association with viral vaccines. But studies have not been able to demonstrate a higher risk for its incidence due to vaccination ( 7 ). The patient, in this case, showed mild symptoms and the second dose of the vaccine did not aggravate the symptoms; therefore a causal association between the vaccine and paresis could not be established. However, vaccine-associated facial paresis was diagnosed in this case due to the lack of any other trigger. This case report can make physicians aware of the probable side effect of viral vector COVID-19 vaccines. Of course, the prevalence of this side effect is very low, and the benefits of vaccination outweigh its side effects. Statements & Declarations Funding: “The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.” Competing Interests: “The authors have no relevant financial or non-financial interests to disclose.” Author Contributions: “All authors contributed to the study conception and design. Negin Mahmoudi Hamidabad wrote the manuscript and involved in the management of the patient, Amir Reza Mafi did the background research, and Meysam Abolmaali wrote, edited and revised the manuscript. All authors read and approved the final manuscript.” Acknowledgement: Special thanks to Dr. Arman Karimi Behnagh for his valuable comments that improved the study. Statement of ethics: This study protocol was reviewed and the need for approval was waived by the Ethics Committee of the Iran University of Medical Sciences. Informed consent was obtained from the patient. Consent to publish statement : Written informed consent was obtained from the patient for publication of this case report and any accompanying images. Data Availability statement : The data is available only by the request. This includes the attached serial number of the vaccine on the vial. References 1. Ozonoff A, Nanishi E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. The Lancet Infectious Diseases. 2021;21(4):450-2. 2. Renoud L, Khouri C, Revol B, Lepelley M, Perez J, Roustit M, et al. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Internal Medicine. 2021. 3. van Tulleken C. Covid-19: Sputnik vaccine rockets, thanks to Lancet boost. bmj. 2021;373. 4. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397(10275):671-81. 5. Pagotto V, Ferloni A, Soriano MM, Díaz M, Golde NB, González MI, et al. Active monitoring of early safety of Sputnik V vaccine in Buenos Aires, Argentina. MEDICINA (Buenos Aires). 2021;81(3):408-14. 6. Holland NJ, Bernstein JM. Bell's palsy. BMJ clinical evidence. 2014;2014. 7. Kamath A, Maity N, Nayak MA. Facial Paralysis Following Influenza Vaccination: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System Database. Clinical Drug Investigation. 2020;40(9):883-9. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1847958","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Case Report","associatedPublications":[],"authors":[{"id":120296729,"identity":"bb0538e4-3b97-4293-bdf4-ba9702a5ee4d","order_by":0,"name":"Negin Mahmoudi Hamidabad","email":"data:image/png;base64,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","orcid":"https://orcid.org/0000-0003-2590-2943","institution":"1.\tDepartment of Neurology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Negin","middleName":"Mahmoudi","lastName":"Hamidabad","suffix":""},{"id":120296871,"identity":"9a863ec8-6e74-4bdf-a3f8-e66d4735c5eb","order_by":1,"name":"Amir Reza Mafi","email":"","orcid":"https://orcid.org/0000-0002-0830-7598","institution":"2.\tSchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Amir","middleName":"Reza","lastName":"Mafi","suffix":""},{"id":120296872,"identity":"b7c90d86-11b8-4b32-91d8-9c8634d987af","order_by":2,"name":"Meysam Abolmaali","email":"","orcid":"https://orcid.org/0000-0002-7039-7854","institution":"3.\tShefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Meysam","middleName":"","lastName":"Abolmaali","suffix":""}],"badges":[],"createdAt":"2022-07-11 20:28:31","currentVersionCode":1,"declarations":{"humanSubjects":true,"vertebrateSubjects":false,"conflictsOfInterestStatement":true,"humanSubjectEthicalGuidelines":true,"humanSubjectConsent":true,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":true,"vertebrateSubjectEthicalGuidelines":false,"coiExplicitlySet":false},"doi":"10.21203/rs.3.rs-1847958/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1847958/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":23776557,"identity":"a6e3e55a-0c6b-443e-b493-53153f6328c3","added_by":"auto","created_at":"2022-07-12 17:03:22","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":480670,"visible":true,"origin":"","legend":"\u003cp\u003eRight sided flattening in Marionette line and nasolabial fold a day after administration of vaccine (1a), no obvious sign of asymmetry after one-month follow-up (1b).\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-1847958/v1/4fad80f2dd8ed7e8cd628fe7.png"},{"id":23776561,"identity":"bab4ef8e-f03b-460a-9671-9da91893007d","added_by":"auto","created_at":"2022-07-12 17:03:24","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":246847,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1847958/v1/bad9202c-126f-45ed-80bd-86f56914751b.pdf"}],"financialInterests":"","formattedTitle":"\u003cp\u003eMild Facial Paresis in a recipient of Gam-COVID-Vac Vaccine: A Case Report.\u003c/p\u003e","fulltext":[{"header":"Background","content":"\u003cp\u003eFacial paralysis has previously been reported as a rare side effect of vaccines such as influenza (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). Among COVID-19 vaccines, there have been reports of facial paralysis associated with BNT162 and 2019-nCoV Vaccine mRNA-1273 vaccines (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e). To our knowledge, there is no report of facial paresis due to the Gam-COVID-Vac vaccination. Gam-COVID-Vac vaccine (rAd26 and rAd5 vector-based) was introduced in Russia in August 2020. In September 2020 the first peer-reviewed study of its I/II phase clinical trials was published and no serious side effects were reported (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e). The results of the Gam-COVID-Vac phase III clinical trial also had no report of serious side effects (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e). The Gam-COVID-Vac vaccine is reported to have above 90 percent efficacy, but still, there is no official report on its safety and efficacy by international organizations (\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eIran is among the countries using the Gam-COVID-Vac vaccine. Despite using this vaccine in many countries, there has been no official report of facial paresis/palsy in association with it. Here, we present a case of mild facial paresis that occurred shortly after Gam-COVID-Vac vaccine administration in a female healthcare worker.\u003c/p\u003e"},{"header":"Case Presentation","content":"\u003cp\u003eA 34-year-old female healthcare worker presented to the emergency department with a unilateral facial weakness a day after receiving the first dose of the Gam-COVID-Vac vaccine. She had a history of migraine attacks (under treatment with Topiramate 25 mg twice a day and Propranolol 40 mg daily). She received the vaccine on February 28th, 2021. A few hours after receiving the vaccine, she developed myalgia, low-grade fever, and rhinorrhea which resolved spontaneously within 3 hours. The next morning, she woke up with a right-sided otalgia and posterior auricular pain which was then followed by unilateral facial weakness (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e1\u003c/span\u003e). In physical examination, the patient had no fever and vital signs were stable. The forehead skin was normal. The Marionette line and nasolabial fold were slightly flattened on the right side and the patient had a mild asymmetrical smile. The eyelids were normal on examination. Ears were normal on examination. There was no evidence of skin rash in physical examination. The review of systems was normal except for the auricular pain and facial weakness. Brain magnetic resonance imaging appeared normal. Complete blood count and C-reactive protein also were normal.\u003c/p\u003e \u003cp\u003eShe did not receive oral glucocorticoids due to the mild state of the symptoms. The patient was followed for one month and her facial paresis resolved after four sessions of physiotherapy (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e1\u003c/span\u003e). A month later, she received the second dose of the vaccine and reported no serious adverse effects.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this study, a case of mild facial paresis following the Gam-COVID-Vac vaccination has been reported that resolved after a few sessions of physiotherapy and did not recur after receiving the second dose of the vaccine.\u003c/p\u003e \u003cp\u003eGam-COVID-Vac was the first registered COVID-19 vaccine in the world but has not been approved by the world health organization, yet. Based on the literature, there has not been any report of facial paresis or palsy associated with the Gam-COVID-Vac vaccine. In a study, the prevalence of facial paralysis-related side effects was 0.6 percent among all side effects and was higher in female vaccine recipients (67.8%). Also, the prevalence of facial palsy was 0.5 percent with other viral vaccines and 0.7 percent with the Influenza vaccine (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e). Facial palsy can occur due to viral infections, trauma, pregnancy, or without known etiology. It is usually self-limiting in nature and may resolve spontaneously (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e). There are many reports regarding the incidence of facial palsy in association with viral vaccines. But studies have not been able to demonstrate a higher risk for its incidence due to vaccination (\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e). The patient, in this case, showed mild symptoms and the second dose of the vaccine did not aggravate the symptoms; therefore a causal association between the vaccine and paresis could not be established. However, vaccine-associated facial paresis was diagnosed in this case due to the lack of any other trigger. This case report can make physicians aware of the probable side effect of viral vector COVID-19 vaccines. Of course, the prevalence of this side effect is very low, and the benefits of vaccination outweigh its side effects.\u003c/p\u003e"},{"header":"Statements \u0026 Declarations","content":"\u003cp\u003e\u003cstrong\u003eFunding:\u0026nbsp;\u003c/strong\u003e\u0026ldquo;The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting Interests:\u003c/strong\u003e \u0026ldquo;The authors have no relevant financial or non-financial interests to disclose.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor Contributions:\u0026nbsp;\u003c/strong\u003e\u0026ldquo;All authors contributed to the study conception and design.\u0026nbsp;Negin Mahmoudi Hamidabad wrote the manuscript and involved in the management of the patient, Amir Reza Mafi did the background research, and Meysam Abolmaali wrote, edited and revised the manuscript.\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eAll authors read and approved the final manuscript.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgement:\u0026nbsp;\u003c/strong\u003eSpecial thanks to Dr. Arman Karimi Behnagh for his valuable comments that improved the study.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatement of ethics:\u0026nbsp;\u003c/strong\u003eThis study protocol was reviewed and the need for approval was waived by the Ethics Committee of the Iran University of Medical Sciences. Informed consent was obtained from the patient.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent to publish statement\u003c/strong\u003e\u003cstrong\u003e:\u003c/strong\u003e Written informed consent was obtained from the patient for publication of this case report and any accompanying images.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability statement\u003c/strong\u003e\u003cstrong\u003e:\u0026nbsp;\u003c/strong\u003eThe data is available only by the request. This includes the attached serial number of the vaccine on the vial.\u003c/p\u003e"},{"header":"References","content":"\u003cp\u003e1.\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Ozonoff A, Nanishi E, Levy O. Bell\u0026apos;s palsy and SARS-CoV-2 vaccines. The Lancet Infectious Diseases. 2021;21(4):450-2.\u003c/p\u003e\n\u003cp\u003e2.\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Renoud L, Khouri C, Revol B, Lepelley M, Perez J, Roustit M, et al. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Internal Medicine. 2021.\u003c/p\u003e\n\u003cp\u003e3.\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;van Tulleken C. Covid-19: Sputnik vaccine rockets, thanks to Lancet boost. bmj. 2021;373.\u003c/p\u003e\n\u003cp\u003e4.\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397(10275):671-81.\u003c/p\u003e\n\u003cp\u003e5.\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Pagotto V, Ferloni A, Soriano MM, D\u0026iacute;az M, Golde NB, Gonz\u0026aacute;lez MI, et al. Active monitoring of early safety of Sputnik V vaccine in Buenos Aires, Argentina. MEDICINA (Buenos Aires). 2021;81(3):408-14.\u003c/p\u003e\n\u003cp\u003e6.\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Holland NJ, Bernstein JM. Bell\u0026apos;s palsy. BMJ clinical evidence. 2014;2014.\u003c/p\u003e\n\u003cp\u003e7. \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Kamath A, Maity N, Nayak MA. Facial Paralysis Following Influenza Vaccination: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System Database. Clinical Drug Investigation. 2020;40(9):883-9.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"Iran University of Medical Sciences","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"COVID-19 vaccine, Gam-COVID-Vac, facial paresis","lastPublishedDoi":"10.21203/rs.3.rs-1847958/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1847958/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eFacial paralysis has\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003epreviously been reported as a rare side effect of vaccines such as influenza (1). Among COVID-19 vaccines, there have been reports of facial paralysis associated with BNT162 and 2019-nCoV Vaccine mRNA-1273 vaccines (2). To our knowledge, there is no report of facial paresis due to the Gam-COVID-Vac vaccination. Gam-COVID-Vac vaccine (rAd26 and rAd5 vector-based) was introduced in Russia in August 2020. In September 2020 the first peer-reviewed study of its I/II phase clinical trials was published and no serious side effects were reported (3). The results of the Gam-COVID-Vac phase III clinical trial also had no report of serious side effects (4). The Gam-COVID-Vac vaccine is reported to have above 90 percent efficacy, but still, there is no official report on its safety and efficacy by international organizations (5).\u003c/p\u003e\u003cp\u003eIran is among the countries using the Gam-COVID-Vac vaccine. Despite using this vaccine in many countries, there has been no official report of facial paresis/palsy in association with it. Here, we present a case of mild facial paresis that occurred shortly after Gam-COVID-Vac vaccine administration in a female healthcare worker.\u003c/p\u003e","manuscriptTitle":"Mild Facial Paresis in a recipient of Gam-COVID-Vac Vaccine: A Case Report.","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-07-12 17:03:20","doi":"10.21203/rs.3.rs-1847958/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"567273e1-f7fd-45f3-b2d1-635899036f11","owner":[],"postedDate":"July 12th, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":13919485,"name":"Neurology"}],"tags":[],"updatedAt":"2022-07-12T17:03:20+00:00","versionOfRecord":[],"versionCreatedAt":"2022-07-12 17:03:20","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1847958","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1847958","identity":"rs-1847958","version":["v1"]},"buildId":"FbvkV6FR0MCFSLy54lSbu","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}